Abstract: A packet processing method and apparatus are provided. The method includes: on a forwarding path of an IPv6 packet, a key node (for example, a firewall) signs a packet, and a downstream apparatus of the key node verifies the signature, to determine whether the packet passes through the key node in a forwarding process. According to this application, the key node performs checking, to effectively prevent a packet which packet header is modified by attackers from bypassing the key node.

Abstract: Provided is a real scene image editing method based on hierarchically classified text guidance, including: firstly selecting a hierarchical multi-label text classification model and hierarchically classify an input style description text; obtaining a latent vector of an indoor scene image and dividing the latent vector; training latent space residual mappers which are divided into four groups for generating details of a layout, an object, an attribute, and a color in the scene image, and selectively training a mapping model with a secondary word obtained by a text classification model; inputting a tertiary word obtained by the text classification model to a contrastive language-image pre-training (CLIP) network and controlling training of the mapping network by utilizing a CLIP loss; hierarchically inputting the latent vector to the mapping network to obtain a bias vector, summing the bias vector with an original vector for inputting to the StyleGAN to obtain an edited image.

Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, myelodysplastic syndrome (MDS) and diabetes.

Abstract: Provided are novel compounds of general formula (I) that inhibit RIP1 kinase or a pharmaceutically acceptable salt thereof, a composition comprising such compounds, and use of such compounds in inhibiting programmed necrosis, inhibiting RIP1 kinase, or treating or preventing a disease that is at least partially mediated by RIP1 kinase.

Abstract: Embodiments of this application disclose a packet sending method. A first IP packet may be obtained, where a packet header of the first IP packet includes a tenant identifier of a tenant corresponding to the first IP packet. After the first IP packet is obtained, the first IP packet is sent to a VAS device, where the VAS device is configured to perform, based on the tenant identifier, a value-added service corresponding to the tenant. Because the packet header of the first IP packet includes the tenant identifier of the tenant corresponding to the first IP packet, after receiving the first IP packet, the VAS device may obtain the corresponding tenant identifier of the tenant by parsing the first IP packet, and further perform, based on the tenant identifier, the value-added service corresponding to the tenant.

Abstract: This disclosure provides compounds of Formula I, compositions comprising the same, and methods of using the same, including use in treating various diseases and conditions, e.g., those involving ferroptosis.

Abstract: Provided are compounds of Formula I, compositions comprising the same, and methods of using the same, including use in treating various diseases and conditions, e.g., those involving ferroptosis.

Abstract: Provided herein are compounds of Formula Ia and Ib, compositions comprising the same, and methods of using the same, including use in treating various diseases and conditions, including those mediated by receptor-interacting protein 1 (RIP1) signaling

Abstract: Disclosed are combinations comprising a therapeutically effective amount of a menin-MLL inhibitor of Formula (I) or a pharmaceutically acceptable salt or a solvate thereof; and a therapeutically effective amount of at least one other therapeutic agent which is a hypomethylating agent, a cytidine deaminase inhibitor, a DNA intercalating agent, a pyrimidine analog, a purine analog, a kinase inhibitor, a CD20 inhibitor, an IDH inhibitor, an immunomodulatory agent or a DHODH inhibitor. Also disclosed are methods for treating a subject who has been diagnosed with cancer using such combinations. Compounds are represented by Formula (I) as follows: wherein R1a, R1b, R2, R3, R4, U, Y1, X1, X2, n1, n2, n3 and n4 are defined herein.

Abstract: It provides compounds of Formula I, compositions comprising the same, and methods of using the same, including use in treating various diseases and conditions, including those mediated by receptor-interacting protein 1 (RIP1) signaling.

Abstract: Disclosed in the present disclosure is a job-shop batch scheduling method based on a dueling double deep Q-network (D3QN) and a genetic algorithm. The present disclosure includes: constructing a mathematical model of a job-shop batch scheduling problem, where a goal of scheduling is to minimize a maximum completion time; determining a batch partition solution to the job-shop batch scheduling problem by the genetic algorithm; crossing and mutating chromosomes in a population; decoding the chromosomes, and obtaining a batch division solution of the workpieces to be machined; and expressing a procedure sequencing problem of the workpiece batches as a disjunctive graph model; performing representative learning on node feature information of a disjunctive graph by using a graph neural network, and extracting a feature state of the procedure sequencing problem; designing a D3QN model structure with priority experience replay, and training the D3QN model; and determining whether a termination condition is satisfied.

Abstract: Systems and methods are provided for controlling one or more optical amplifiers of a C+L band photonic line system (30) of a telecommunications network in which C-band signals and L-band signals may be transmitted. In one implementation, a method (130) may execute a traffic managing module (23). When executed, the traffic managing module (23) may be configured to enable a processing device (12) to calculate (132) a gain correction profile based on a difference between a saved baseline transmission profile (84) and a measured transmission profile (94) of a surviving band of a photonic line system (30) when another band of the photonic line system (30) is missing or impacted. The traffic managing module (23) may further be configured to enable the processing device (12) to apply (134) the gain correction profile to a respective optical amplifier (46) of the photonic line system (30) to compensate for the difference.

Abstract: Systems and methods of capacity changes in an optical network having a plurality of optical sections include, responsive to a request for a capacity change for a plurality of channels, bundling the plurality of channels into different steps such that all of the plurality of channels are assigned to a step of the different steps; and causing implementation of the different steps across the plurality of optical sections, wherein each section performs the implementation and the bundling between corresponding Optical Add/Drop Multiplexer (OADM) nodes independently and asynchronously from one another.

Abstract: Provided are azetidine cyclic urea compounds that inhibit cellular necrosis and/or human receptor interacting protein 1 kinase (RIP1), including corresponding sulfonamides, and pharmaceutically acceptable salts, hydrates and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof with an effective amount of the compound or composition, and detecting a resultant improvement in the persons health or condition.

Abstract: Systems and methods include, responsive to a request for capacity change of X channels, X is an integer >1, on an optical section (14) and at an Optical Add/Drop Multiplexer (OADM) node (12) in an optical network (10), dividing optical spectrum on the optical section into M slots, M is an integer >1, such that the capacity change of X channels takes a maximum of N steps, N is an integer >1; and performing the capacity change of X channels in up to the N steps in an interleaved manner that changes a subset of the X channels in each of the N steps. For each step, the performing can include a maximum of M/N slots of the M slots with spacing between each of the M/N slots not used for the capacity change in a corresponding step. The spacing can be f, (N+f), (2N+f), . . . , M over the optical spectrum, where f is each step, f=1, 2, . . . , N.

Abstract: A packet processing method and apparatus are provided. The method includes: on a forwarding path of an IPv6 packet, a key node (for example, a firewall) signs a packet, and a downstream apparatus of the key node verifies the signature, to determine whether the packet passes through the key node in a forwarding process. According to this application, the key node performs checking, to effectively prevent a packet which packet header is modified by attackers from bypassing the key node.

Abstract: The present disclosure discloses a method for the preparation of sulfinpyrazone, which is produced in two steps with a total yield of 48%, wherein thiophenol as the starting material is electrocatalytically coupled with dichloroethane to obtain 2-chloroethyl phenyl sulfoxide, which then undergoes a substitution reaction with 1,2-diphenyl-3,5-pyrazolidinedione to produce sulfinpyrazone. Compared with the prior art, the present method is characterized by high yield, short steps, less three wastes, good chemical selectivity, no need to use strong bases and oxidants, safe and simple operation, and easy to realize industrial production.

Abstract: A gel electrophoresis system includes a base module and a camera module. The base module includes a cassette slot for receiving a gel electrophoresis cassette, and a light element that functions to illuminate the gel electrophoresis cassette. The camera module is selectively attachable to and detachable from the base module. When attached to the base module, the camera module facilitates imaging of the gel electrophoresis cassette and provides additional imaging capabilities.

Abstract: Provided are piperazine cyclic urea compounds that inhibit cellular necrosis and/or human receptor interacting protein 1 kinase (RIP1), pharmaceutically acceptable salts, hydrates and stereoisomers thereof. Provided are also pharmaceutical compositions, methods of making, and methods of use which include treating a person in need thereof with an effective amount of the compound or composition, and detecting a resultant improvement in the person's health or condition.

Abstract: The present disclosure provides compounds including piperazine heterocyclic amide urea compounds that inhibit cellular necrosis and/or human receptor interacting protein 1 kinase (RIP1), including corresponding sulfonamides, and pharmaceutically acceptable salts, hydrates and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof with an effective amount of the compound or composition, and detecting a resultant improvement in the person's health or condition.